Chronic lymphocytic leukemia (CLL) is a cancer affecting the blood and bone marrow, characterized by the gradual accumulation of abnormal lymphocytes. Risk factors include older age, a family history of CLL, and exposure to chemicals. Symptoms can be variable and can include fatigue, weakness, night sweats, weight loss, lymph node enlargement, splenomegaly, infections, and bone pain. As the disease progresses, it can lead to complications like anemia, thrombocytopenia, and autoimmune hemolytic anemia. Diagnosis involves blood tests, bone marrow biopsy, imaging studies, and cytogenetic testing to identify specific abnormalities and guide treatment decisions.
Chronic lymphocytic leukemia (CLL) treatment is individualized based on the disease’s stage, risk, and patient’s health. Early-stage patients often follow a “watch and wait” approach, monitoring blood counts and disease progression. When necessary, targeted therapies, chemotherapy, and immunotherapy are used. BR chemotherapy, a combination of bendamustine and rituximab, is a common and effective treatment for patients who don’t qualify for more aggressive approaches like stem cell transplantation.
Mr. Sree Mohesh Chandro Roy from Bangladesh successfully received BR Chemotherapy for Chronic Lymphocytic Leukemia at Yashoda Hospitals, Hyderabad, under the supervision of Dr. Ganesh Jaishetwar, Consultant Hematologist, Hemato-Oncologist & Bone Marrow Transplant Physician.